Human Papillomavirus Associated Diseases Pipeline Analysis Report 2025

Human papillomavirus-associated diseases encompass a range of conditions, including cervical, oropharyngeal, and anogenital cancers. These diseases account for a significant global health burden, with a pooled prevalence of 31% for any HPV and 21% for high-risk HPV. HPV-16 remains the most common genotype at 5%, followed by HPV-6 at 4%. There is a high unmet clinical need for improved therapies, as current treatment options, such as surgery and radiation, have limitations. The growing focus on immunotherapies, targeted therapies, and HPV-specific therapeutic vaccines is expected to drive advancements in human papillomavirus-associated diseases drug development, expanding the treatment pipeline in the coming years.

Report Coverage

The Human Papillomavirus Associated Diseases Drug Pipeline Insight Report by the publisher gives comprehensive insights into human papillomavirus-associated diseases therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for human papillomavirus-associated diseases. The human papillomavirus-associated diseases report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The human papillomavirus-associated diseases pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with human papillomavirus-associated disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to human papillomavirus-associated diseases.

Human Papillomavirus Associated Diseases Drug Pipeline Outlook

Human papillomavirus-associated diseases include cervical, oropharyngeal, anal, and genital cancers, as well as warts. It spreads through skin-to-skin and sexual contact, with high-risk strains causing malignancies. Persistent infection with oncogenic HPV types, particularly HPV-16 and HPV-18, leads to cellular changes, increasing the risk of cancer development over time.

Human papillomavirus-associated diseases are treated with surgical excision, radiation, and chemotherapy for cancerous lesions. Immunotherapies, targeted drugs, and HPV vaccines aid prevention and treatment. Advanced therapies, including therapeutic vaccines and antiviral agents, are in development to address unmet clinical needs and improve outcomes for HPV-related conditions.

Human Papillomavirus Associated Diseases Epidemiology

The global prevalence of human papillomavirus is 31% for any HPV and 21% for high-risk strains. HPV-16 is the most common genotype at 5%, followed by HPV-6 at 4%. Nearly one in three men worldwide have at least one genital HPV type, while one in five carries high-risk strains. Cervical HPV prevalence is highest in Latin America and the Caribbean at 16%, Eastern Europe at 14%, and Southeast Asia at 14%. The increasing focus on immunotherapies, targeted treatments, and HPV-specific vaccines is expected to drive significant advancements in therapeutics for HPV-associated diseases.

Human Papillomavirus Associated Diseases - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of human papillomavirus-associated diseases drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Peptides
• Gene Therapies
• RNA-based Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Human Papillomavirus Associated Diseases - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total human papillomavirus-associated diseases clinical trials.

Human Papillomavirus Associated Diseases - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the human papillomavirus-associated diseases pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, RNA-based therapies, and others. The human papillomavirus-associated diseases report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human papillomavirus-associated diseases.

Human Papillomavirus Associated Diseases Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the human papillomavirus-associated diseases drug pipeline includes the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed human papillomavirus-associated diseases therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is a list of a few players involved in human papillomavirus-associated diseases clinical trials:

• Antiva Biosciences
• Labo'Life
• Beijing Health Guard Biotechnology, Inc.
• Serum Institute of India Pvt. Ltd.
• Merck Sharp & Dohme LLC
• RinuaGene Biotechnology Co., Ltd.
• Shanghai Bovax Biotechnology Co., Ltd.
• Catalysis SL
• NexImmune Inc.
• Eisai Co., Ltd.

Human Papillomavirus Associated Diseases Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for human papillomavirus-associated diseases. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of human papillomavirus-associated disease drug candidates.

Drug: 2

LPAPI®
2LPAPI®, a novel treatment belonging to the immunotherapy drug class, is being evaluated in a Phase IV clinical trial sponsored by Labo'Life. The study aims to assess its efficacy in clearing genital high-risk human papillomavirus (HR-HPV) infections. This randomized, placebo-controlled study will enroll approximately 284 participants.

Drug: ABI-2280

ABI-2280 vaginal inserts, developed by Antiva Biosciences, are being evaluated in a Phase Ib/II study to assess their safety, tolerability, and efficacy in women with persistent high-risk human papillomavirus (HPV) infections. The study aims to assess viral clearance and optimal dosing regimens. Expected to conclude by February 2026, the trial plans to enroll an estimated 160 participants across multiple cohorts.

Biological: NEXI-003

NEXI-003, an autologous T-cell therapy targeting HPV-16, HPV-18, and Survivin, is being evaluated in a Phase I trial sponsored by NexImmune Inc. The study aims to assess the safety of NEXI-003 in patients with relapsed or refractory HPV-related oropharyngeal cancers. It is expected to conclude by August 2027 and intends to recruit around 36 participants.

Reasons To Buy This Report

The Human Papillomavirus Associated Diseases Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for human papillomavirus-associated diseases. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into human papillomavirus-associated diseases collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Human Papillomavirus Associated Diseases - Pipeline Insight Report

• Which companies/institutions are leading the human papillomavirus-associated diseases drug development?
• What is the efficacy and safety profile of human papillomavirus-associated disease pipeline drugs?
• Which company is leading the human papillomavirus-associated diseases pipeline development activities?
• What is the current human papillomavirus-associated diseases commercial assessment?
• What are the opportunities and challenges present in the human papillomavirus-associated diseases drug pipeline landscape?
• What is the efficacy and safety profile of human papillomavirus-associated disease pipeline drugs?
• Which company is conducting major trials for human papillomavirus-associated disease drugs?
• Which companies/institutions are involved in human papillomavirus-associated disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in human papillomavirus-associated diseases?

This product will be delivered within 3-5 business days.